Unlock the Editor’s Digest independent
FT Editor Rouhlah Khalaf selects her favorite stories in this weeklist.
China’s excess crisis is a profitable opportunity. Within half of the Chinese adults, only 2030 of 2030 because they are overweight or obese. That’s about 900m. That is much larger than the US and to dominate.
This is the stimulation to noven noddisk. Danish drug Maker is already enjoying the global wind from its blockbuster to lose weight loss. In November 2024, the country’s revenue increased by 13 per cent (2.6 billion) last year.
But this Golden era may be less. Novo Nordis Market in China They are a thick.
At least 15 Chinese drugmakers perform a range of 15 Chinese drugmakers to sell their own versions of semaglotide. In them, Huadong Medicine Chairs are in front of the Chair, already in the last step of clinical trials. Pear Hangzhou Giuuu Juuuu Jean engineering applied for a treatment for a treatment. This is a similar clinical effectiveness and security of the claims. A long list of biotech starters and the established drugmers will be held behind the two.
The opportunity is not confined to China. The growing need for weight loss medicines, such as India has the public health concern, which is increasingly increasingly increasingly increasing. Huadong Medicine stake in the last six months rises a quarter of a quarter. This reflects expectations of their weight loss expectations.
It is not only a business challenge by Novo Nordis patent loss – China’s Pharma region. For decades, local drug movements were primarily known as generic manufacturers and build low calls of existing drugs instead of their own innovation. In recent years, the local drug cleaners will move local drug cleaners and areas such as Barisi Biosian, Emuterapy and European regulatory authorities.
While Hongroon semaggoldine alternatives, when the hostage of homerun semaggal, another action in commercialization, the Global Pharma industry will be represented from the presence of a low-cost producer.
June. yoon@ft.com
